Why we measure it

APOE ε4 is the most significant known genetic risk factor for late-onset Alzheimer's disease — by a large margin. The landmark 1993 study by Corder and colleagues, published in Science, established the gene-dose relationship: carrying one ε4 allele (ε3/ε4 genotype, present in approximately 20–25% of the population) increases lifetime risk of Alzheimer's disease approximately 3–4-fold compared to ε3/ε3. Carrying two ε4 alleles (ε4/ε4 genotype, approximately 2–3% of the population) increases risk approximately 8–12-fold. The ε4 allele is also the most important known genetic modifier of cardiovascular risk beyond cholesterol levels: ε4 carriers have higher LDL cholesterol at any given dietary intake, a greater LDL response to dietary saturated fat, and impaired clearance of post-meal triglyceride-rich lipoproteins. Across both disease domains — cardiovascular and neurodegenerative — APOE genotype does not alter the probability of disease to a fixed absolute level; it modifies the slope of risk accumulation over decades. This is precisely why knowing it early matters: the interventions that most effectively modify risk in ε4 carriers (aggressive LDL lowering starting earlier, greater dietary fat modification, optimised metabolic health, sleep architecture, and aerobic fitness) are implemented over years and decades, not in response to symptoms. APOE genotype contextualises every other marker in the Blueprint protocol — it tells you how much margin you have and how early you need to start.

Why once at enrollment

APOE genotype is determined at conception and does not change. A single test at enrollment produces a lifetime result. There is no clinical or scientific rationale for repeat testing.

What movement means

APOE genotype is a categorical result, not a continuous variable. The clinical meaning is determined by which two alleles are present. The ε2 allele reduces Alzheimer's and cardiovascular risk; the ε4 allele increases both. The ε3 allele is neutral. ε2/ε2 homozygosity, though associated with favourable Alzheimer's and cardiovascular risk, carries a distinct liability: a markedly elevated risk of type III hyperlipoproteinemia (dysbetalipoproteinemia), a rare but serious lipid disorder characterised by elevated IDL and chylomicron remnants with both high triglycerides and high non-LDL cholesterol. Any ε2 carrier with an abnormal lipid panel should be evaluated for this condition.

In the protocol